CTNNB1 and glioblastoma: Specifically, we observed an overall downregulation in several critical points belonging to these pathways [i.e., total-protein -levels of AKT/MTOR/S6K1/CTNNB1/TP53/HIF1A; phosphorylated-protein levels of AKT/MTOR/S6K1/PDK1 and expression levels of CCND1 and MYC) and an upregulation of phosphorylated-TP53 levels, in different GBM models (in vitro and/or in vivo) in response to SF3B1 blockade.